How would China achieve WHO’s target of eliminating HCV by 2030?

Li, Mingyang; Zhang, Hui; Wei, Lai

doi:10.1080/14787210.2019.1675509

Cited by 30 publications

(38 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Barriers to access to treatment are also compounded with many other hurdles in China, most notably the limited health system readiness with a very low rate of proactive screening and diagnosis [20] . The awareness of the disease among the general public has been low, many patients only receive a test after showing clinical symptoms [21] . The knowledge and understanding of the disease of non-specialist physicians, especially at the primary level of care, also becomes a barrier to treatment scale-up [22] .…”

Section: Overview Of the Situation Of Hepatitis C-common Grounds And Differences Between Malaysia And Chinamentioning

confidence: 99%

“…Multi-organizational collaborations across sectors including the government, research institutes, professional associations, healthcare providers, pharmaceutical companies, and civil societies in China were not strong enough to integrate all resources to combat and eliminate HCV [21] . Such a situation has been improving especially during the ongoing formulation of the National Work Plan for Elimination of Hepatitis C as a Public Health Threat (2021-2030).…”

Section: Strategic Responses-success Of Malaysia and Efforts Made In Chinamentioning

confidence: 99%

See 1 more Smart Citation

What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review

Sun

Cheng

Hassan

et al. 2021

The Lancet Regional Health - Western Pacific

View full text Add to dashboard Cite

Background: To discuss a range of strategic options for China to improve the accessibility of direct antiviral agents (DAAs) as the treatment for hepatitis C. Methods: We adopted a narrative review approach for comprehensive comparisons and in-depth analyses of the country context, and barriers of increasing the DAA treatment rate of hepatitis C in Malaysia and China, and how the two countries have been navigating the hepatitis C agenda. Findings: Malaysia adopted a series of successful strategies to scale up the diagnosis of hepatitis C and DAA treatment, which have valuable implications for China. Interpretation: The potential game-changing strategies for China to adapt from Malaysian experiences range from the stepping-up of political commitment and leadership, enhanced market competition, simplified and decentralized treatment at the strengthened primary care level, integrated healthcare services, coordinated government initiatives, to multi-organizational participation and civil society's active role in raising public awareness, and training of non-specialist physicians. Embarking on scale-up of hepatitis C treatment marks another contribution of China to improve the health of not only the Chinese citizens but also mankind, which is an important component for building healthy Chinese and global communities. Funding: No funding supported this study.

show abstract

Section: Overview Of the Situation Of Hepatitis C-common Grounds And Differences Between Malaysia And Chinamentioning

confidence: 99%

Section: Strategic Responses-success Of Malaysia and Efforts Made In Chinamentioning

confidence: 99%

What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review

Sun

Cheng

Hassan

et al. 2021

The Lancet Regional Health - Western Pacific

View full text Add to dashboard Cite

show abstract

“…In addition, direct-acting antiviral (DAA) therapy has been shown to have reliable treatment compliance and outcomes in Chinese patients since it was approved in 2017. 40 Therefore, consideration should be given to the coverage of DAAs by the national health insurance to facilitate the elimination of hepatitis C. This study is a multicentre study with a large sample size, with participants who had been laboratory-confirmed, and we used standardised scale to measure depression, which made the study stronger. However, this study suffers from two main limitations.…”

Section: Knowledge Of Hcv Among Hcv-positive Patients Was Generally Lowmentioning

confidence: 99%

Knowledge, attitude and psychological status of patients living with hepatitis C in five provinces in China: a cross-sectional survey

et al. 2021

View full text Add to dashboard Cite

ObjectiveThis study investigated the knowledge, attitudes and psychological status of hepatitis C virus (HCV)-positive patients through a cross-sectional survey to provide scientific strategies for improving their treatment compliance and quality of life.SettingThe research was conducted in nine hospitals in five provincial administrative regions in China, namely Inner Mongolia, Jilin, Beijing, Hebei and Sichuan.ParticipantsA total of 457 patients were recruited for this study and 409 patients were included in the final analysis. The participants were 215 men and 194 women, with an average age of 59 years.Primary and secondary outcome measuresThe primary outcomes were scores on scales assessing knowledge, attitudes and psychological status. The secondary outcomes were transmission of HCV, preference regarding the mode in which information about HCV was provided and factors affecting treatment.ResultsBlood transfusion was the most common route of HCV transmission (42.7%), followed by surgery (15.9%) and blood donation/sale (8.7%). The misunderstanding of HCV and negative attitudes towards other HCV-positive patients were relatively common among HCV-positive patients and were more pronounced among rural and ethnic minority populations. HCV-positive patients were generally categorised as possibly having symptoms of depression. Patients with negative attitudes were more likely to have symptoms of depression (OR=0.6, 95% CI 0.4 to 0.8).ConclusionsHCV-positive patients had a poor understanding of HCV and a negative attitude towards other HCV-positive patients. It is very important to develop effective health education strategies to improve the knowledge, attitudes and mental health of HCV-positive patients and enhance treatment compliance.

show abstract

“…To attain these targets, 90% of chronically infected cases should be diagnosed and 80% should be treated. Individuals infected with HCV should, therefore, be identified [ 5 ]. Accurate, efficient and cost-effective screening and diagnosis of HCV infection is critical for further therapeutic decisions.…”

Section: Introductionmentioning

confidence: 99%

A study based on four immunoassays: Hepatitis C virus antibody against different antigens may have unequal contributions to detection

Jiang

Chang

Yan

et al. 2021

Virol J

View full text Add to dashboard Cite

Background All commercial Hepatitis C virus antibody (anti-HCV) assays use a combination of recombinant antigens to detect antibody response. Antibody responses to individual antigenic regions (core, NS3/4 and NS5) used in assays have not been investigated. Methods In this study, we quantified HCV viral load, tested anti-HCV with four commercial assays (Ortho-ELISA, Murex-ELISA, Architect-CMIA and Elecsys-ECLIA) in 682 plasma specimens. In antigenic region ELISA platform, microwells were coated with three antigens: core (c22-3), NS3/4 (c200) and NS5 individually. The signal-to-cutoff (S/Co) values of different assays, and antibody responses to individual antigens were compared. The specimens were divided into HCV RNA positive group, anti-HCV consistent group, and anti-HCV discrepant group. Results Anti-core and anti-NS3/4 were simultaneously detected in 99.2% of HCV RNA positive specimens and showed great consistency with total anti-HCV signals. Responses to the core region were more robust than those to the NS3/4 region in anti-HCV consistent group (p < 0.001). Anti-NS5 only occurred in companying with responses to the core and NS3/4 antigens, and failed to affect the final anti-HCV positive signals. In anti-HCV discrepant group, 39.0% of positive signals could not be traced back to any single antigenic region. Conclusion Antibody responses to the core and NS3/4 antigens were stronger, whereas responses to the NS5 antigen were the weakest, indicating that individual antigenic regions played different roles in total anti-HCV signals. This study provides an impetus for optimizing commercial anti-HCV assays.

show abstract

How would China achieve WHO’s target of eliminating HCV by 2030?

Cited by 30 publications

References 62 publications

What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review

What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030 – a narrative review

Knowledge, attitude and psychological status of patients living with hepatitis C in five provinces in China: a cross-sectional survey

A study based on four immunoassays: Hepatitis C virus antibody against different antigens may have unequal contributions to detection

Contact Info

Product

Resources

About